Email updates

Keep up to date with the latest news and content from Cardiovascular Diabetology and BioMed Central.

Open Access Original investigation

Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report

Ikuko Nakamura1, Jun-ichi Oyama1*, Hiroshi Komoda1, Aya Shiraki1, Yoshiko Sakamoto1, Isao Taguchi2, Atsushi Hiwatashi1, Aiko Komatsu1, Masayoshi Takeuchi3, Sho-ichi Yamagishi4, Teruo Inoue2 and Koichi Node1

Author Affiliations

1 Department of Cardiovascular Medicine, Saga University, Saga 849-8501, Japan

2 Department of Cardiovascular Medicine, Dokkyo Medical University, Mibu, Tochigi, Japan

3 Department of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, Uchinada, Ishikawa, Japan

4 Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Fukuoka, Japan

For all author emails, please log on.

Cardiovascular Diabetology 2014, 13:15  doi:10.1186/1475-2840-13-15

Published: 14 January 2014



The purpose of this study was to elucidate the effects of glimepiride on the levels of biomarkers related to cardiovascular regulation in patients with type 2 diabetes mellitus.

Methods and results

Thirty-four patients with type 2 diabetes received glimepiride for 24 weeks. Significant decreases in the levels of glyceraldehyde-derived advanced glycation end products, (glycer-AGE: toxic AGE), eotaxin and fibroblast growth factor (FGF)-2 were recognized after the administration of glimepiride. Moreover, there were trends for there to be increases in the levels of granulocyte-colony stimulating factor (G-CSF) and granulocyte macrophage-colony stimulating factor (GM-CSF), and decreases in the levels of fractalkine, soluble CD40 ligand (sCD40L), macrophage inflammatory protein (MIP)-β, vascular endothelial growth factor (VEGF) and soluble receptor for AGE (sRAGE).


Glimepiride may have potent anti-oxidative, anti-inflammatory and angiogenic properties and it may potentially repair tissue damage by decreasing the levels of toxic AGE and increasing colony-stimulating factors.

Glimepiride; Advanced glycation end products; Cytokines/chemokines; Growth factors; Diabetes mellitus type 2